Literature DB >> 19683979

Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours.

D Cvejic1, S Selemetjev, S Savin, I Paunovic, S Tatic.   

Abstract

The aim of this study was to gain better insight into molecular changes which reflect disturbances in the balance between proliferation and apoptosis during progression of thyroid malignancy from papillary microcarcinoma (PMC) via clinically manifest papillary carcinoma (PTC) to anaplastic carcinoma (ATC). The apoptosis related molecules (Bcl-2, Bax) and proliferation related marker (PCNA) were analysed immunohistochemically in 120 archival cases comprising PMC (n=34), PTC (n=52) and ATC (n=34). In addition, in situ apoptotic cell death was analysed by the TUNEL method. The average Bcl-2 staining score did not differ between PMC and PTC (p>0.05), but was significantly lower in ATC (p<0.05).The Bax score was higher in PTCs and ATCs than in PMCs (p<0.05). Due to these changes, the Bcl-2/Bax ratio showed a marked decrease from PMC to ATC (p<0.05), while proliferation activity increased significantly from PTC to ATC (p<0.05). Despite high Bax expression, the rate of apoptotic cell death was low in the investigated carcinomas, especially in ATC, i.e. the increase in proliferative activity was not counterbalanced with appropriate cell death. Differences were found in the expression of apoptotic molecules (Bcl-2 and Bax), their ratio (Bcl-2 /Bax) and in the rate of apoptotic cell death and proliferative activity between PMC, PTC and ATC, indicating that disturbances in the balance between apoptosis and proliferation, in favour of the latter, occur gradually during the progression of malignancy in thyroid tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683979     DOI: 10.4081/ejh.2009.65

Source DB:  PubMed          Journal:  Eur J Histochem        ISSN: 1121-760X            Impact factor:   3.188


  6 in total

1.  Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma.

Authors:  Lu Feng; Mei Li; Qiu-Ping Zhang; Zheng-Ai Piao; Zhao-Hui Wang; Shen Lv
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

2.  Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.

Authors:  Tijana Išić; Svetlana Savin; Dubravka Cvejić; Ilona Marečko; Svetislav Tatić; Marija Havelka; Ivan Paunović
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  Histochemistry through the years, browsing a long-established journal: novelties in traditional subjects.

Authors:  C Pellicciari
Journal:  Eur J Histochem       Date:  2010-12-16       Impact factor: 3.188

4.  Identifying pathological biomarkers: histochemistry still ranks high in the omics era.

Authors:  C Pellicciari; M Malatesta
Journal:  Eur J Histochem       Date:  2011-12-07       Impact factor: 3.188

5.  An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis.

Authors:  Monika Lamba Saini; Caroline Bouzin; Birgit Weynand; Etienne Marbaix
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

6.  The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.

Authors:  Martina Broecker-Preuss; Nina Becher-Boveleth; Stefan Müller; Klaus Mann
Journal:  Cancer Cell Int       Date:  2016-04-02       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.